MedTrace Logo

PharmacofMRI of Anxiolytic Medications (Pregabalin)

NCT00706836 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function. In this case, the medication pregabalin will be used. The investigators hypothesize that pregabalin (at doses of 50 mg and 200 mg, versus placebo) will yield a reduction in amygdala and insula activity (in a dose-dependent fashion) during emotion processing using fMRI.

Conditions

  • Anxiety Disorders

Interventions

DRUG

Pregabalin 50mg

One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan

DRUG

Pregabalin 200 MG

One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan

DRUG

placebo

One dose of matched oral placebo to be administered one hour prior to fMRI scan

Sponsors & Collaborators

Principal Investigators

  • Murray B Stein, MD, MPH · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00706836 on ClinicalTrials.gov